spacer
home > white papers > Delivering Fit For Purpose Biomanufacturing CHO Cell Lines - Fujifilm Diosynth Biotechnologies
WHITE PAPERS
logo_Fujifilm_D.JPG

Fujifilm Diosynth Biotechnologies

phone +44 (0)1642 363511
email enquiries@fujifilmdb.com
web http://www.fujifilmdiosynth.com
email Fujifilm Diosynth Biotechnologies Belasis Avenue Billingham TS23 1LH

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
Delivering Fit For Purpose Biomanufacturing CHO Cell Lines
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>


White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). It’s about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>


Industry Events

Outsourcing in Clinical Trials West Coast

3-4 March 2020, Hyatt Regency San Francisco Airport

Last year's event was attended by 700+ clinical trial stakeholders. Following its success, we are pleased to forecast the 2020 edition will be even in larger scale, with a great speaker line up and engaging content. This edition aims to give attendees practical take-aways which they can apply to their studies.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement